124 related articles for article (PubMed ID: 18504652)
21. Genetic variation in IGF-1 and breast cancer risk in Ashkenazi carriers and noncarriers of BRCA1/2 mutations.
Khoury-Shakour S; Lejbkowicz F; Barnett-Griness O; Tamir A; Pinchev M; Rennert G
Eur J Cancer Prev; 2009 Sep; 18(5):361-7. PubMed ID: 19543094
[TBL] [Abstract][Full Text] [Related]
22. Re: Radiation-induced breast cancer.
Kopans DB
J Natl Cancer Inst; 1994 Jan; 86(1):66-7. PubMed ID: 8271291
[No Abstract] [Full Text] [Related]
23. BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo.
Quaresima B; Romeo F; Faniello MC; Di Sanzo M; Liu CG; Lavecchia A; Taccioli C; Gaudio E; Baudi F; Trapasso F; Croce CM; Cuda G; Costanzo F
Clin Cancer Res; 2008 Nov; 14(21):6797-803. PubMed ID: 18980973
[TBL] [Abstract][Full Text] [Related]
24. Enhanced biological effectiveness of low energy X-rays and implications for the UK breast screening programme.
Redpath JL; Mitchel RE
Br J Radiol; 2006 Oct; 79(946):854-5; author reply 855-7. PubMed ID: 16980679
[No Abstract] [Full Text] [Related]
25. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
[TBL] [Abstract][Full Text] [Related]
26. Platinum sensitivity in a BRCA1 mutation carrier with advanced breast cancer.
Rhiem K; Wappenschmidt B; Bosse K; Köppler H; Tutt AN; Schmutzler RK
Clin Oncol (R Coll Radiol); 2009 Aug; 21(6):448-50. PubMed ID: 19249193
[TBL] [Abstract][Full Text] [Related]
27. Founder effect of the BRCA1 5382insC mutation in Brazilian patients with hereditary breast ovary cancer syndrome.
da Costa EC; Vargas FR; Moreira AS; Lourenço JJ; Caleffi M; Ashton-Prolla P; Martins Moreira MA
Cancer Genet Cytogenet; 2008 Jul; 184(1):62-6. PubMed ID: 18558292
[TBL] [Abstract][Full Text] [Related]
28. [Systematic breast self-examination is not a useful screening procedure, except in hereditary or familial increased risk of breast cancer].
Kaas R; Rutgers EJ
Ned Tijdschr Geneeskd; 2008 Oct; 152(43):2317-8. PubMed ID: 19024059
[TBL] [Abstract][Full Text] [Related]
29. The p53 Arg72Pro and Ins16bp polymorphisms and their haplotypes are not associated with breast cancer risk in BRCA-mutation negative familial cases.
De Vecchi G; Verderio P; Pizzamiglio S; Manoukian S; Bernard L; Pensotti V; Volorio S; Ravagnani F; Radice P; Peterlongo P
Cancer Detect Prev; 2008; 32(2):140-3. PubMed ID: 18640791
[TBL] [Abstract][Full Text] [Related]
30. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis.
Shen J; Ambrosone CB; DiCioccio RA; Odunsi K; Lele SB; Zhao H
Carcinogenesis; 2008 Oct; 29(10):1963-6. PubMed ID: 18660546
[TBL] [Abstract][Full Text] [Related]
31. The molecular pathology of hereditary breast cancer.
Palacios J; Robles-Frías MJ; Castilla MA; López-García MA; Benítez J
Pathobiology; 2008; 75(2):85-94. PubMed ID: 18544963
[TBL] [Abstract][Full Text] [Related]
32. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
[TBL] [Abstract][Full Text] [Related]
33. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
34. High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers.
Maehle L; Apold J; Paulsen T; Hagen B; Løvslett K; Fiane B; Van Ghelue M; Clark N; Møller P
Clin Cancer Res; 2008 Nov; 14(22):7569-73. PubMed ID: 19010876
[TBL] [Abstract][Full Text] [Related]
35. The phases of disclosing BRCA1/2 genetic information to offspring.
Clarke S; Butler K; Esplen MJ
Psychooncology; 2008 Aug; 17(8):797-803. PubMed ID: 18646247
[TBL] [Abstract][Full Text] [Related]
36. Mammary tumor development in dogs is associated with BRCA1 and BRCA2.
Rivera P; Melin M; Biagi T; Fall T; Häggström J; Lindblad-Toh K; von Euler H
Cancer Res; 2009 Nov; 69(22):8770-4. PubMed ID: 19887619
[TBL] [Abstract][Full Text] [Related]
37. Genetic services have value beyond BRCA1/2 testing.
Hall MJ
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):686. PubMed ID: 19208665
[No Abstract] [Full Text] [Related]
38. X-rays--a carcinogen.
Linton O
Acad Radiol; 2005 May; 12(5):665. PubMed ID: 15866142
[No Abstract] [Full Text] [Related]
39. Radiation risks.
Linton O
Acad Radiol; 2006 Nov; 13(11):1445. PubMed ID: 17070465
[No Abstract] [Full Text] [Related]
40. Ionizing radiation, breast cancer, and ataxia-telangiectasia.
Swift M
J Natl Cancer Inst; 1994 Nov; 86(21):1571-2. PubMed ID: 7932817
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
